Form 4: Maravai LifeSciences Director Acquires Shares for GTCR-Affiliated Entity, Disclaims Pecuniary Interest

Luke Joseph Marker, a Director and 10% owner of Maravai LifeSciences Holdings, Inc., acquired 89,139 shares of Class A Common Stock as restricted stock units, holding them indirectly for a GTCR-affiliated entity.

Summary

• Luke Joseph Marker, identified as a Director and 10% owner of Maravai LifeSciences Holdings, Inc. (MRVI), reported a transaction on a Form 4 filing.
• On June 16, 2025, Mr. Marker acquired 89,139 shares of Class A Common Stock.
• These shares were awarded as restricted stock units (RSUs) under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan.
• The RSUs were acquired at a price of $2.16 per share.
• The vesting schedule for these RSUs is upon the earlier of one year from the grant date (June 16, 2025) or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.
• Following this transaction, Mr. Marker beneficially owns a total of 138,055 shares of Class A Common Stock.
• The reporting person holds these securities indirectly for the benefit of a GTCR-affiliated entity and explicitly disclaims any pecuniary interest in them.

Sentiment

Score: 6

Explanation: The transaction is a routine RSU award to a director, which generally aligns interests positively. However, the explicit disclaimer of pecuniary interest by the reporting person slightly tempers the direct positive signal typically associated with insider acquisitions.

Positives

• The award of restricted stock units to a director and 10% owner aligns management's long-term interests with shareholder value through an incentive plan.
• The transaction represents an increase in the total number of shares beneficially owned by a key insider, albeit indirectly.

Negatives

• The reporting person, Luke Joseph Marker, explicitly disclaims any pecuniary interest in the acquired securities, indicating the shares are held for the benefit of a GTCR-affiliated entity rather than for his direct personal financial gain.

Risks

• The disclaimer of pecuniary interest by the reporting person may suggest that the acquisition does not reflect a direct personal conviction in the company's stock performance, but rather a holding on behalf of an affiliated entity.

Future Outlook

The restricted stock units are scheduled to vest upon the earlier of one year from the grant date (June 16, 2025) or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders, indicating a future milestone for the compensation structure.

Management Comments

• "The Reporting Person disclaims any pecuniary interest in the securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16."

Industry Context

This Form 4 filing illustrates a common executive compensation practice within the life sciences industry, where restricted stock units are used to incentivize long-term performance and align management interests with shareholder value. The involvement of a private equity firm like GTCR, through an affiliated entity, in the ownership structure is also typical for companies that have received private equity backing.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) as part of an incentive plan is a standard compensation practice in the life sciences sector, comparable to how companies such as Thermo Fisher Scientific or Danaher Corporation structure executive compensation to foster long-term commitment.
• The vesting schedule (earlier of one year or next annual meeting) is typical for such equity awards.
• The indirect ownership structure, where a board member holds shares for a private equity-affiliated entity and disclaims personal pecuniary interest, is consistent with private equity investment models where board representation often serves the fund's interests.

Related Party Transactions

• The acquisition of shares by Luke Joseph Marker, a Director and 10% owner, for the benefit of a GTCR-affiliated entity, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The RSU award aligns the interests of a significant director and 10% owner with long-term shareholder value, potentially fostering confidence. However, the disclaimer of pecuniary interest means the direct personal financial stake of the individual is limited.
• Management/Employees: The transaction is part of an incentive plan, which can motivate the reporting person.

Next Steps

• Vesting of the 89,139 restricted stock units upon the earlier of June 16, 2026 (one year from grant) or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

Key Dates

Recommendation

Keywords

Maravai LifeSciences Holdings Inc, MRVI, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Award, Director, 10% Owner, GTCR, Beneficial Ownership